Impact of immunosuppression on the immune response to SARS-CoV-2 infection: A mechanistic study.
COVID-19
SARS-CoV-2
cytokines
immunosuppression
transplant
Journal
Transplant infectious disease : an official journal of the Transplantation Society
ISSN: 1399-3062
Titre abrégé: Transpl Infect Dis
Pays: Denmark
ID NLM: 100883688
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
revised:
26
09
2021
received:
13
07
2021
accepted:
27
09
2021
pubmed:
21
10
2021
medline:
25
12
2021
entrez:
20
10
2021
Statut:
ppublish
Résumé
The optimal management of immunosuppression in transplant patients infected with COVID-19 is unknown. We performed an in vitro study to determine the effect of individual immunosuppressive agents on SARS-CoV-2-specific T-cell cytokine expression. Convalescent peripheral blood mononuclear cells from eleven non-immunosuppressed patients with COVID-19 were preincubated with clinically relevant concentrations of immunosuppressive drugs (tacrolimus, mycophenolate, sirolimus, prednisone) and then stimulated with a SARS-CoV-2 peptide pool. Supernatants were analyzed by 14-plex high sensitivity T-cell cytokine array. With increasing concentrations of tacrolimus, there was a trend to reduction in the release of IL-2 (p = .0137), and IFN-γ (p = .0147) in response to peptide stimulation. There was also a subsequent trend toward a Th2 phenotype, indicated by lower IFN-γ:IL-13 ratio (p = .0663) and IFNγ:IL-4 ratio (p = .0176). Sirolimus appeared to be associated with a proinflammatory cytokine release, including TNF-α (p = .0027) and IL-1β (p = .0016), in response to SARS-CoV-2 peptides. In contrast, mycophenolate and prednisone did not influence the SARS-CoV-2-specific cytokine response. These are preliminary findings only, with larger studies required to inform clinical recommendations.
Identifiants
pubmed: 34668283
doi: 10.1111/tid.13743
pmc: PMC8646571
doi:
Substances chimiques
Cytokines
0
Mycophenolic Acid
HU9DX48N0T
Prednisone
VB0R961HZT
Sirolimus
W36ZG6FT64
Tacrolimus
WM0HAQ4WNM
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13743Subventions
Organisme : the Ajmera Transplant Centre
Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Lancet Respir Med. 2020 Apr;8(4):420-422
pubmed: 32085846
Am J Transplant. 2005 Jun;5(6):1483-9
pubmed: 15888058
Transpl Infect Dis. 2021 Dec;23(6):e13743
pubmed: 34668283
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
Pharmacy (Basel). 2020 Apr 03;8(2):
pubmed: 32260162
J Transl Med. 2008 Jun 09;6:29
pubmed: 18541023
Clin Infect Dis. 2020 Jul 28;71(15):721-722
pubmed: 32129842
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
J Immunol. 2014 Jun 15;192(12):5451-8
pubmed: 24907378
J Clin Invest. 2020 May 1;130(5):2620-2629
pubmed: 32217835
Transplantation. 2009 Nov 27;88(10):1161-8
pubmed: 19935369
Transpl Infect Dis. 2020 Oct;22(5):e13378
pubmed: 32573882
Clin Infect Dis. 2021 Dec 6;73(11):e4090-e4099
pubmed: 32766815
Cell Rep Med. 2021 Mar 16;2(3):100208
pubmed: 33564749
Front Immunol. 2020 Jun 16;11:1441
pubmed: 32612615
J Immunol. 2021 Jan 1;206(1):37-50
pubmed: 33208459
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
N Engl J Med. 2004 Dec 23;351(26):2715-29
pubmed: 15616206
Immune Netw. 2018 Oct 17;18(5):e33
pubmed: 30402328
Nat Immunol. 2020 Nov;21(11):1336-1345
pubmed: 32887977
Clin Ther. 2000;22 Suppl B:B101-121
pubmed: 10823378
Transplantation. 2013 Feb 15;95(3):448-55
pubmed: 23274966
Lancet. 2020 Nov 14;396(10262):1595-1606
pubmed: 33065034
Asian Pac J Allergy Immunol. 2020 Mar;38(1):1-9
pubmed: 32105090